[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lithuanian University of Health Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":413},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,47,73,95,126,157,187,214,245,266,288,315,342,365,391],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641448","effects-of-direct-artery-injection-on-prostate-cancer-drug-delivery-and-tumor-uptake-imaging-based-prediction-of-treatment-effectiveness-100641448",false,"NCT07656337","Effects of Direct Artery Injection on Prostate Cancer Drug Delivery and Tumor Uptake: Imaging-Based Prediction of Treatment Effectiveness","Impact of Intra-Arterial PSMA Injection on Distribution and Tumor Uptake: Texture Analysis and Dose Radicality Prediction in Prostate Cancer","IAPSMA","Inclusion Criteria:\n\n* Adult male patients with biopsy-proven prostate adenocarcinoma up to stages ≤T3bN1 by initial preoperative examination, with no distant metastases (M0) on ⁶⁸Ga-PSMA PET\u002FCT.\n* Systemic therapy-naive patients scheduled for radical prostatectomy with\u002Fwithout pelvic lymph node dissection with curative intent.\n* High-risk localized or locally-advanced prostate cancer according to European Association of Urology criteria, including one of the following:\n\n  1. Prostate-specific antigen \\> 20ng\u002FmL2 or ISUP grade 4\u002F5.\n  2. Clinical T stage cT3-4\\* and\u002For N1 disease (involvement of lymph nodes at or below the bifurcation of the common iliac arteries), any ISUP grade, and any\n* High PSMA avidity on ⁶⁸Ga-PSMA PET\u002FCT, defined as SUVmax ≥20.\n* Normal baseline hematological function.\n* Normal serum biochemistry.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Patients with other (non-adenocarcinoma) biopsy-proven histology of prostate cancer.\n* Patients with low-risk prostate cancer according to European Association of Urology criteria, including any of the following:\n\n  1. Prostate-specific antigen \\\u003C10 ng\u002Fml.\n  2. International Society of Urological Pathology grade group 1.\n  3. Clinical T stage T1-T2a digital rectal examination.\n* Prior radiotherapy or systemic therapy for prostate cancer.\n* Prostate cancer with low PSMA avidity (SUVmax \\\u003C20) on ⁶⁸Ga-PSMA PET\u002FCT.\n* Evidence of distant metastatic spread (M1) on ⁶⁸Ga-PSMA PET\u002FCT.\n* Contraindications for radical prostatectomy.\n* Major comorbidities and laboratory abnormalities that might confound the results of the trial or interfere with the patient's ability to participate.\n* Refusal to participate in the trial.","MALE","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether intra-arterial (IA) administration of 68Ga-PSMA improves tumor uptake and distribution compared with standard intravenous (IV) administration in patients with localized high-risk prostate cancer. The study will also evaluate the safety of the IA procedure and investigate whether advanced PET\u002FCT imaging features can help predict the radiation dose needed for future personalized 177Lu-PSMA radioligand therapy.\n\nThe main questions it aims to answer are:\n\n* Does intra-arterial 68Ga-PSMA administration result in higher and more homogeneous tumor uptake than standard intravenous administration?\n* Can PET\u002FCT texture analysis and dosimetric modeling predict the radiation dose required to achieve a curative effect with 177Lu-PSMA therapy?\n* What radiation exposure and procedure-related risks are associated with intra-arterial administration for patients and medical staff?\n\nResearchers will compare PSMA uptake and distribution after intravenous and intra-arterial administration of 68Ga-PSMA using PET\u002FCT imaging.\n\nParticipants will:\n\n* Undergo a standard intravenous 68Ga-PSMA PET\u002FCT scan.\n* Undergo a second 68Ga-PSMA PET\u002FCT scan following selective intra-arterial administration through the prostatic artery.\n* Have imaging data analyzed using advanced texture analysis and voxel-based dosimetry methods.\n* Undergo radical prostatectomy according to standard clinical care, with pathological analysis of surgical specimens.\n* Be monitored for adverse events, radiation exposure, and procedural safety throughout the study.",[27,28],"Prostate Cancer","Prostate Adenocarcinoma",[30,31,32,33],"Prostate cancer","Intraarterial PSMA injection","Texture analysis","Dose radicality prediction","NOT_YET_RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":21},"2026-08-01",{"date":42,"type":21},"2028-10-31",{"name":44,"class":45},"Lithuanian University of Health Sciences","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100638724","influence-of-alveolar-bone-drilling-and-anatomical-position-on-integration-100638724","NCT07589140","Influence of Alveolar Bone Drilling and Anatomical Position on Integration","Influence of Alveolar Bone Drilling and Anatomical Position on the Primary Stability, Osseointegration and Functioning of Immediately Placed Dental Implants","Inclusion Criteria:\n\n* ≥ 18 years old.\n* healthy patients without medical contraindications for dental implantation surgery.\n* removable and non-molar teeth indicated for extraction in both jaws\n* healthy soft tissues (bleeding on probing \\\u003C 20%, plaque index \\\u003C 25%);\n* intact alveolar bone walls post-extraction\n* signed informed consent form and permission to use the obtained data for research purposes.\n\nExclusion Criteria:\n\n* Smokers (≥ 10 cigarettes per day);\n* history of uncontrolled periodontitis;\n* uncontrolled diabetes\u002Falcoholism;\n* use of drugs that may affect healing;\n* persons who, due to health status, cannot be considered capable of reasonably assessing their interests;","ALL",{"count":56,"type":21},124,[24],"The goal of this clinical trial is to learn if alveolar bone drilling and anatomical position of an immediately placed dental implant has influence on the primary stability, osseointegration and function. It aims to answer these questions:\n\n* Does absence of alveolar drilling before implant placement give the same result as traditional osteotomy with apical drilling?\n* Is palatinal root position of implant as succesful as central position?\n\nResearchers will compare crestal bone levels and primary stability of the implant after insertion in the groups. Subjects will be assigned to groups, acoording to clinical situation. Study groups:\n\n1. Dental implants will be placed in the extraction socket with an apical osteotomy.\n2. Dental implants will be placed in the extraction socket without performing an osteotomy.\n3. Dental implants will be placed in the centre of the extracted maxillary molar socket.\n4. Dental implants will be placed into the palatal root socket of the extracted maxillary molar.",[60,61,62],"Dental Implant","Bone Grafting","Immediate Dental Implant Placement",[64],"dental implant","2026-06-01",{"date":67,"type":38},"2026-06-03",{"date":69,"type":21},"2026-07",{"date":71,"type":21},"2028-05",{"name":44,"class":45},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100640807","out-of-hospital-cardiac-arrest-epidemiology-and-outcomes-in-western-lithuania-2022-2028-100640807","NCT07622082","Out-of-hospital Cardiac Arrest Epidemiology and Outcomes in Western Lithuania 2022-2028","Prehospital Processess Optimization and Emergency Medical Services' Dispatcher's Actions Modeling Impact on Quality of Cardiopulmonary Resuscitation After Sudden Cardiac Arrest","Inclusion Criteria:\n\n* people experiencing out-of-hospital cardiac arrest\n\nExclusion Criteria:\n\n* all others",{"count":81,"type":21},4000,"1 Year","OBSERVATIONAL","Out-of-hospital cardiac arrest rate is common problem, because of high mortality rate. It is not clear incidence rate, epidemiology and outcomes in Lithuania",[86],"Out-of-hospital Cardiac Arrest (OHCA)","2026-05-27",{"date":89,"type":38},"2026-06-02",{"date":91,"type":21},"2026-09-01",{"date":93,"type":21},"2030-01-01",{"name":44,"class":45},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":83,"phases":4,"briefSummary":105,"conditions":106,"keywords":112,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100632684","prognostic-value-of-early-postoperative-prostate-specific-antigen-for-oncological-outcomes-after-radical-prostatectomy-100632684","NCT07516886","Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy","PPSARP","Inclusion Criteria:\n\n* Patient is an adult biological male.\n* Patient has morphologically confirmed and untreated prostate cancer.\n* Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy.\n* Patient is informed about this observational study and has signed the informed consent form.\n\nExclusion Criteria:\n\n* Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation.\n* Patient received neoadjuvant prostate cancer treatment.\n* Patient is set to receive adjuvant treatment.\n* Patient has any contraindications for the operation.",{"count":103,"type":21},500,"10 Years","This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.\n\nNo investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.",[107,108,109,110,111],"Prostate Cancer (Post Prostatectomy)","Prostate Cancer (Adenocarcinoma)","Prostate Cancer (Diagnosis)","Prostate Specific Antigen","Radical Prostatectomy",[113,114,115,116],"prostate cancer","persistent prostate-specific antigen","prostate-specific antigen","radical prostatectomy","RECRUITING","2026-04-01",{"date":120,"type":38},"2026-04-08",{"date":122,"type":38},"2024-01-22",{"date":124,"type":21},"2039-07",{"name":44,"class":45},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":54,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":46},"100521676","respiratory-and-cardiovascular-alterations-in-patients-with-chronic-obstructive-pulmonary-disease-100521676","NCT06072690","Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease","The Impact of Dual Bronchodilation on Respiratory and Cardiovascular Systems in Patients With Newly Diagnosed Moderate-to-severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Aged 40 years and older\n* Smoking index of 10 pack-years and more\n* Newly diagnosed chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 30-79 percent of predicted and forced expiratory volume in 1 second to forced vital capacity ratio (FEV1\u002FFVC) less than 70 percent of predicted.\n\nExclusion Criteria:\n\n* Active lung infection\n* Present or previously treated lung cancer\n* Alpha-1 antitrypsin deficiency\n* Diagnosed interstitial lung disease\n* Previously diagnosed asthma\n* Diagnosed chronic hypercapnic respiratory failure\n* Treatment with systemic glucocorticoids\n* Unstable ischaemic heart disease\n* Pregnancy\n* Present cardiac arrhythmias\n* Uncontrolled arterial hypertension\n* Dementia and other mental states that determine patient's inability to consent\n* Other medical conditions that in the opinion of the investigator disqualify the subject for inclusion","40 Years",{"count":135,"type":21},80,"Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and\u002For exacerbations) due to abnormalities of the airways (e.g. bronchitis, bronchiolitis) and\u002For alveoli (emphysema) that lead to persistent, often progressive, airflow obstruction.\n\nIt is a major cause of disability and death worldwide. Moreover, people with COPD often have cardiovascular diseases (CVDs) that are associated with increased risk for hospitalization and prolonged stay as well as all-cause and CVD-related mortality. Nevertheless, CVDs in patients with COPD are tend to be underestimated in clinical practice. Mechanisms that define the relation between COPD and cardiovascular morbidity include lung hyperinflation, hypoxia, pulmonary hypertension, systemic inflammation and oxidative stress, exacerbation, shared risk factors and COPD phenotypes. In the past years, some authors have announced that COPD treatment with dual bronchodilation may not only improve pulmonary function and quality of life, but also have a positive effect on cardiac function. However, there is a lack of studies with treatment-naïve patients that would describe the initial effect of dual bronchodilation on respiratory and cardiovascular systems. In this study we aimed to evaluate the effect of initial dual bronchodilation on the quality of life, respiratory and cardiovascular systems in patients with newly-diagnosed chronic obstructive pulmonary disease.",[138,139,140,141],"Chronic Obstructive Pulmonary Disease Moderate","Chronic Obstructive Pulmonary Disease Severe","Cardiovascular Diseases","Quality of Life",[143,144,145,146,147,148],"COPD","cardiac autonomic integrity","cardiac function","dual bronchodilation","biomarkers","quality of life","2026-03-28",{"date":151,"type":38},"2026-04-02",{"date":153,"type":38},"2021-04-15",{"date":155,"type":21},"2026-08-31",{"name":44,"class":45},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":168,"studyType":83,"phases":4,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":46},"100614811","depressive-symptoms-cognitive-impairment-and-outcomes-in-hospitalized-chronic-heart-failure-patients-100614811","NCT07284446","Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients","Prevalence of Depressive Symptoms and Cognitive Impairment and Their Association With Worse Outcomes in a Cohort of Hospitalized Patients With Chronic Heart Failure","DSCI-CHF","Inclusion Criteria:\n\n* patient hospitalized primarily for CHF exacerbation;\n* clinically stable, able to provide informed consent;\n* do not have severe cognitive impairment that would preclude valid questionnaire administration.\n\nExclusion Criteria:\n\n* hospitalization for acute heart failure;\n* total length of hospital stay \\\u003C96 hours;\n* absence of transthoracic echocardiography (TTE) within the last 12 months and no TTE planned;\n* severe visual impairment preventing completion of the visual part of the Montreal Cognitive Assessment;\n* refusal to participate.","85 Years",{"count":167,"type":21},300,"12 Months","The goal of this observational study is to learn about the prevalence of depressive symptoms and cognitive impairment and their association with worse outcomes in a cohort of hospitalized patients between the ages of 18 ang 85 years with chronic heart failure. The main question it aims to answer is:\n\n• Does the presence of depressive symptoms and cognitive impairment lead to worse outcomes in a cohort of hospitalized patients with chronic heart failure? Participants who are hospitalized due to exacerbation of chronic heart failure will answer survey questions to assess their cognitive function and depressive symptoms.",[171,172,173],"Congestive Heart Failure Chronic","Cognitive Impairment, Mild","Depressive Symptoms Mild to Moderate in Severity",[175,176,177,178,179],"Congestive Heart Failure","Mild Cognitive Impairment","Long-term Outcomes","Mild Depressive Symptoms","Rehospitalizations","2025-12-02",{"date":182,"type":38},"2025-12-16",{"date":180,"type":38},{"date":185,"type":21},"2028-12-02",{"name":44,"class":45},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":54,"minAge":193,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100600452","the-change-in-psychoemotional-state-of-individuals-with-dementia-syndrome-applying-art-therapy-100600452","NCT07097675","The Change in Psychoemotional State of Individuals With Dementia Syndrome Applying Art Therapy","Inclusion Criteria:\n\n* diagnosed with dementia;\n* MMSE ≥11 (mild to moderate cognitive impairment);\n* stable somatic condition;\n* vision and hearing sufficient to assess cognitive function and to administer interventions;\n* familiar with the purpose and conduct of the study;\n* signed an informed consent form.\n\nExclusion Criteria:\n\n* MMSE \\\u003C 11 points (severe cognitive impairment);\n* chronic, unstable somatic conditions;\n* Inability to comprehend the tasks;\n* Lack of knowledge of the Lithuanian language;\n* Refusal to take part in the study.","60 Years",{"count":195,"type":21},71,[24],"Due to global demographic changes, a notable trend of population aging has emerged, resulting in an increased prevalence of health conditions typically associated with the elderly. One such condition is cognitive impairment-dementia syndrome. Currently, 40,000 cases of dementia are registered in Lithuania (Health Information Centre), with projections estimating 81,000 cases by 2050 \\[13\\].\n\nThe care of individuals with dementia syndrome requires a holistic approach, incorporating both pharmacological and non-pharmacological interventions. The effectiveness of pharmacological treatment is limited: no highly effective drugs currently exist for Alzheimer's disease (available drugs have limited pathogenetic and symptomatic effects), there are no specific treatments for other forms of dementia, and the long-term use of medications to manage behavioral symptoms is associated with adverse effects. The OECD equates the routine use of neuroleptics with poor quality care \\[2\\]. Furthermore, even when medications are prescribed, non-pharmacological interventions should be applied concurrently \\[5\\].\n\nOne recommended method is arts therapy. Art therapy is a recognized psychosocial treatment that improves attention, perception, memory, and mood in people with dementia. However, there is a lack of studies evaluating the effectiveness of art therapy specifically in improving the psycho-emotional state of individuals with dementia syndrome.\n\nPharmacological treatments commonly used for dementia syndrome offer limited long-term benefits \\[23\\]. As the number of individuals affected by dementia continues to grow, increasing attention is being paid to improving their quality of life, social integration, and emotional well-being through non-pharmacological means. International guidelines recommend creative and artistic activities tailored to individual preferences, skills, and abilities, including music and dance \\[19\\]. One of the increasingly recognized interventions is art therapy \\[5\\]. Systematic review findings support the inclusion of various psychological interventions in the treatment of individuals with dementia who suffer from depression and\u002For anxiety disorders \\[3\\].\n\nGlobally, research most commonly explores the impact of art therapy on cognitive functions, quality of life, behavior, and psychological well-being in individuals with dementia \\[3; 4\\]. However, the FEATS scale is rarely used to assess emotional state changes. Although psycho-emotional issues are highly relevant and widely studied, relatively few studies explore these within the context of art therapy. Most existing research is qualitative, with a lack of quantitative studies.\n\nThe novelty of this planned study lies not only in the specificity of the participants but also in the application of the FEATS scale. While FEATS is widely used in research, few studies apply this instrument to explore the psycho-emotional state of people with dementia syndrome. The scale's authors and other researchers recommend expanding its use across diverse populations to assess its validity for different patient groups \\[10; 21\\].\n\nThis study will help reveal the effectiveness of art therapy as a non-invasive and non-pharmacological intervention for improving the psycho-emotional state of individuals with dementia syndrome. The research findings will contribute positively to patient well-being and the advancement of nursing science. Art therapy sessions are expected to improve participants' emotional state and reduce signs of anxiety, depression, and stress. This will provide scientific evidence of the effectiveness of art therapy and allow for the validation of the FEATS scale for assessing the psycho-emotional state of people with dementia syndrome.",[199],"Dementia",[201,202,203,204,205],"dementia","art therapy","depression","anxiety","stress","2025-07-24",{"date":208,"type":38},"2025-07-31",{"date":210,"type":21},"2025-09-01",{"date":212,"type":21},"2027-12-01",{"name":44,"class":45},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":46},"100577586","effectiveness-of-modern-physical-agents-in-the-treatment-of-pelvic-floor-dysfunctions-100577586","NCT06800222","Effectiveness of Modern Physical Agents in the Treatment of Pelvic Floor Dysfunctions","The Effectiveness of Modern Physical Agents in Treating Pelvic Floor Dysfunctions, Improving Functional State, Life Quality, and Biosocial Functions During First-stage Pelvic Rehabilitation.","EMPHAT-PFD","Inclusion Criteria:\n\n1. Patients older than 18 years old.\n2. One or more signs characteristic of pelvic floor dysfunctions are identified: elimination function disorders, pelvic organ prolapse, scar(s) (and lack of tissue mobility) in the perineum, pelvic floor muscle tone\u002Fstrength disorders (hypoactivity\u002Fhyperactivity), neuromuscular control disorders, sexual dysfunctions, pain in the pelvis, perineum.\n3. Not a single exclusion criterion has been established.\n4. Subjects capable of signing informed consent.\n\nExclusion Criteria:\n\n1. Oncological diseases or being actively investigated for oncological diseases.\n2. Any contraindications to methods of functional state examination or physical agents in the pelvic area that will be used in the study\n3. Individuals who refuse a detailed clinical examination of the perineum and pelvic floor muscles, functional testing, and\u002For functional ultrasound examination.\n4. Patients with urinary tract, prostate, genital, and other infections.\n5. Patients with inflammatory bowel diseases (ulcerative colitis, Crohn's disease, etc.).\n6. Persons for whom other health care professionals have already planned treatment of pelvic dysfunctions or other diseases during the expected participation period in the study that may interfere with participation in the study and\u002For significantly change the health status of the patient's pelvic floor.\n7. Pregnant or planning to become pregnant during the expected period of rehabilitation interventions.",{"count":223,"type":21},250,[24],"This clinical trial aims to determine whether adding modern physical agents (high-intensity laser therapy, magnetotherapy, radial shock wave therapy, kinesiotaping) in conjunction with classical rehabilitation interventions produces superior outcomes in treating pelvic floor dysfunction compared to classical rehabilitation interventions alone. It will also assess the safety of these agents in the context of pelvic floor dysfunction rehabilitation. The main questions it aims to answer are:\n\nDoes adding modern physical agents to the treatment of pelvic floor dysfunction improve symptoms, impairments in functional state, quality of life, and biosocial functions more effectively than classical interventions alone?\n\nParticipants who experience pelvic floor dysfunction during primary rehabilitation will receive:\n\nEither an individualized rehabilitation intervention plan comprising 20 classical procedures in combination with modern physical agents or classical interventions alone. Rehabilitation will take place in the outpatient rehabilitation department. Patients will visit the clinic for a comprehensive functional state assessment and then for individualized procedures; the entire plan will be delivered over three months, after which participants will return for follow-up checkups and assessments after the procedures and again after six months.",[227],"Pelvic Floor Dysfunctions",[229,230,231,232,233,234,235,236],"pelvic floor dysfunctions","pelvic pain","urgency","incontinece","vaginismus","constipation","erectile dysfunction","irritable bladder","2025-01-24",{"date":239,"type":38},"2025-01-29",{"date":241,"type":21},"2025-03-01",{"date":243,"type":21},"2029-09-09",{"name":44,"class":45},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":46},"100526821","changes-in-function-of-the-upper-limb-with-physiotherapy-100526821","NCT06139731","Changes in Function of the Upper Limb With Physiotherapy","Changes in Function of the Upper Limb With Physiotherapy for Acute Burns: a Pilot Study","Inclusion Criteria:\n\n* patients aged 18-69 years\n* had burns on the upper limb(s) with or without burns on the upper body\n* burns involving ≥ 10% total body surface area (TBSA) with the presence of deep partial thickness or full thickness burns\n* who agreed to take part in the study\n\nExclusion Criteria:\n\n* inability to perform or understand tests\n* other injuries (fractures, brain injury)\n* central and peripheral nervous system disorders\n* amputation\n* with burns on the head, hands, feet, and genital area","65 Years",{"count":254,"type":21},17,"This paper describes a pilot clinical study designed to compare changes in ROM, muscle strength and functional recovery of the upper limb during the inpatient treatment period of burn injury.",[257],"Burn of Upper Limb, Except Wrist and Hand","2025-01-22",{"date":260,"type":38},"2025-01-27",{"date":262,"type":38},"2020-01-01",{"date":264,"type":21},"2026-01-30",{"name":44,"class":45},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100567906","changes-in-electrocardiographic-ecg-ventricular-repolarization-and-transthoracic-impedance-cardiography-icg-parameters-in-patients-with-covid-19-and-after-the-disease-persistence-and-prognostic-significance-of-these-changes-100567906","NCT06674278","Changes in Electrocardiographic (ECG) Ventricular Repolarization and Transthoracic Impedance Cardiography (ICG) Parameters in Patients with COVID-19 and After the Disease: Persistence and Prognostic Significance of These Changes","Inclusion Criteria:\n\n* Patient was hospitalized and treated in LUHS Kaunas Hospital for acute COVID-19 2 years ago (starting from 2022 January 1st).\n* During hospitalization COVID-19 was verified with PCR test from nasopharyngeal swab.\n\nExclusion Criteria:\n\n* COVID-19 was not verified with PCR test from nasopharyngeal swab.\n* Patients who are unable to give informed consent for participation in study; vulnerable individuals: students if their participation is related to their studies, employees of healthcare institutions subordinate to the researcher, residents of social care institutions, and soldiers during their active military service.\n* Patients with an implanted pacemaker or cardioverter-defibrillator.\n* Patients whose permanent residence is not in Lithuania and who are not Lithuanian citizens.\n* Patients for whom it is not possible to perform ECG and ICG tests due to various circumstances.\n* Pregnant individuals (including individuals who were pregnant during the disease).",{"count":273,"type":21},215,"The aim of this study is to determine the relationship between changes in resting electrocardiography (ECG) ventricular repolarization parameters, transthoracic impedance cardiography (ICG) parameters, and COVID-19, to assess the relationship between ECG changes after COVID-19 and heart rhythm disorders (arrhythmias), cardiovascular events (the onset and exacerbation of cardiovascular diseases), the persistence of changes two years after the illness, and to identify prognostic ventricular repolarization parameters in patients with and after COVID-19.\n\nIt is expected that the results obtained during the study will help predict long-term cardiovascular complications in these patients, aiming to prevent them by providing recommendations for the long-term monitoring of individuals who have recovered from COVID-19. Additionally, the investigators hope to propose a new ECG ventricular repolarization parameter that could be used in the future for prognostic assessment in patients with other diseases as well.",[276,277,278,279],"Post COVID-19","Ventricular Repolarization","Arrhythmias","Impedance Cradiography","2024-11-03",{"date":282,"type":38},"2024-11-05",{"date":284,"type":21},"2024-11",{"date":286,"type":21},"2027-01",{"name":44,"class":45},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":46},"100437815","informative-of-surface-electromyography-and-prognostic-factors-in-assessing-the-recovery-of-balance-and-gait-after-stroke-100437815","NCT04981184","Informative of Surface Electromyography and Prognostic Factors in Assessing the Recovery of Balance and Gait After Stroke","Informative of Surface Electromyography and Determination of Prognostic Factors in Assessing the Probability of Recovery of Balance and Gait Parameters in Patients With Ischemic Stroke on Acute Rehabilitation","Inclusion Criteria:\n\n* Cerebral infarction for the first time;\n* Age from 18 to 89 years old;\n* Muscle strength according to the Oxford scale is 3-5 points;\n* Able to walk without the help of others;\n* Is able to communicate and understand instructions properly;\n* Agrees to participate in the study (voluntary, explicit, informed written consent to participate).\n\nExclusion Criteria:\n\n* Muscle strength according to the Oxford scale is 0-2 points;\n* Unable to walk without the help of others;\n* Sensorimotor aphasia or other perceptual disorders;\n* Do not sign the informed consent.","89 Years",{"count":297,"type":21},100,[24],"The aim of the biomedical research is to determine the informativeness and prognostic factors of surface electromyography by assessing the probability of recovery of balance and gait parameters in the second stage of rehabilitation of persons with cerebral infarction.",[301],"Brain Ischemia",[303,304,305,306],"Surface Electromyography","Gait","Balance","Ischemic stroke","2024-10-16",{"date":309,"type":38},"2024-10-17",{"date":311,"type":38},"2019-07-22",{"date":313,"type":21},"2026-09-30",{"name":44,"class":45},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":165,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":46},"100557293","hemodynamic-variations-during-remote-ischemic-conditioning-in-critical-ill-patients-100557293","NCT06536231","Hemodynamic Variations During Remote Ischemic Conditioning in Critical Ill Patients","HERICA","Inclusion Criteria:\n\n* aged over 18 years,\n* admitted to the intensive care unit,\n* monitored with a transpulmonary thermodilution device with calibrated pulse contour analysis (Pulsion Medical Systems, Munich, Germany),\n* decision by the physician in charge to perform passive leg raising.\n\nExclusion Criteria:\n\n* pregnancy,\n* advanced malignancy,\n* peripheral artery disease affecting both arms,\n* head trauma,\n* deep vein thrombosis in the lower limbs,\n* intra-abdominal hypertension, defined as an intra-abdominal pressure greater than 12 mmHg.",{"count":323,"type":21},50,[24],"The main objectives of this study are to evaluate the changes in hemodynamics occurring during the remote ischemic conditioning (RIC) procedure and to compare the hemodynamic responses elicited by passive leg raising before and after the RIC intervention.",[327],"Critical Illness",[329,330,331,332,333],"Remote ischemic conditioning","Passive leg raising","Hemodynamic","Perfusion index","Fluid responsiveness","2024-08-10",{"date":336,"type":38},"2024-08-13",{"date":338,"type":38},"2024-01-01",{"date":340,"type":21},"2025-03-31",{"name":44,"class":45},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":54,"minAge":349,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":46},"100539057","the-pattern-of-dry-eye-disease-after-cataract-surgery-100539057","NCT06298890","The Pattern of Dry Eye Disease After Cataract Surgery","Ocular Surface and Corneal Morphological Changes After the Cataract Surgery and Associations With Inflammatory Biomarkers","Inclusion Criteria:\n\n* Cataract patients from 50 to 90 years old who underwent uncomplicated phacoemulsification performed by one (and same) experienced surgeon.\n* Patients with no underlying ocular surface diseases (keratitis, keratoconjunctivitis and others).\n* Patients who previously did not undergo any ophthalmic surgery.\n\nExclusion Criteria:\n\n* Patient expressed his wish to not participate in the study or discontinue it when already enrolled.\n* Severe dry eye disease diagnosed with OSDI\u002FDEQ-5 and at least one of the following tests: TBUT less than 10 seconds, tear osmolarity higher than 308 mOsm\u002Fl or positive corneal staining.\n* Glaucoma.\n* Diabetes mellitus.\n* Systemic connective tissue disease, autoimmune disease.\n* Neurologic conditions including stroke, Bell's palsy, Parkinson's, trigeminal nerve dysfunction.\n* Patients who underwent refractive surgery (LASIK or PRK).\n* Contact lens users.\n* One or more of the following concomitant medications: psychiatric medicines, antihistamines and\u002For hormonal replacement.\n* Patients who are already regularly using topical drops or ointments.","50 Years","90 Years",{"count":297,"type":21},"This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up.",[354,355,356],"Dry Eye Disease","Cataract","Ocular Surface Disease","2024-03-01",{"date":359,"type":38},"2024-03-07",{"date":361,"type":21},"2024-03",{"date":363,"type":21},"2027-09",{"name":44,"class":45},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":252,"enrollmentInfo":372,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":374,"conditions":375,"keywords":380,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":390},"100537492","validation-of-the-lithuanian-version-of-the-bnss-cdss-and-the-scors-100537492","NCT06278532","Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS","Validation of the Lithuanian Version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale","Inclusion Criteria:\n\n* age 18 - 65 years old;\n* Diagnosis of F20, F25 or F21 according to ICD-10;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Age younger than 18 or older than 65 years old;\n* Did not sign the informed consent form;\n* Legally inactive person\n* Patients with a comorbid or primary diagnosis of mental retardation according to ICD-10 (F70 - F79);\n* Patients with a comorbid or primary diagnosis of mental and behavioural disorders due to psychoactive substance use (F10 - F19)\n* Patients with a comorbid of primary diagnosis of organic, including symptomatic, mental disorders (F00 - F09)",{"count":373,"type":21},200,"This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test.",[376,377,378,379],"Schizophrenia","Negative Symptoms in Schizophrenia","Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)","Cognitive Deficit",[381],"Schizophrenia, Negative symptoms, Depressive symptoms of Schizophrenia, Cognitive deficits of Schizophrenia","2024-02-19",{"date":384,"type":38},"2024-02-26",{"date":386,"type":38},"2023-12-11",{"date":388,"type":21},"2026-12-11",{"name":44,"class":45},2,{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":46},"100468372","phase-2-neoadjuvant-therapy-vs-standard-therapy-in-locally-advanced-rectal-cancer-100468372","NCT05378919","Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer","Evaluation and Comparison of the Efficacy of a New Standard Pre-operative Chemotherapy for Stage II and III Colorectal Cancer According to the FOLFOX4 Regimen With Routine Chemoradiation Therapy","RECTUM2015","Inclusion Criteria:\n\n* diagnosed with rectal adenocarcinoma;\n* radiologically measurable tumor size;\n* general condition (ECOG 0-2 points);\n* stage II or III rectal tumor clinically (pelvic MRI and endorectal ultrasound),\n* in the absence of long-term spread of the disease (confirmed by radiological examinations (computed tomography of the thorax and abdomen));\n* during preoperative proctoscopy, the tumor is detected 0 -15 cm from the anus;\n* Blood tests 28 days before the start of treatment:\n\nand general blood count: neutrophils greater than 1.5x10 9 \u002F l, platelets greater than 100 x 10 9 \u002F l, Hemoglobin greater than 80 g \u002F l, liver enzymes (Aspartate aminotransferase (AST\u002FGOT), alanine aminotransferase (ALT\u002FGPT) not more than 3 times upper limit), and renal function (creatinine up to 1.5 times the upper limit of normal) is normal; women of childbearing potential - negative pregnancy test;\n\n• A signed informed consent form.\n\nExclusion Criteria:\n\n* patients with signs of intestinal obstruction at the start of treatment;\n* previous lower abdominal radiation therapy;\n* other tumors over a five-year period;\n* pregnant or breastfeeding women;\n* men and women of childbearing potential who do not agree to use adequate contraception;\n* Patient co-morbidities that would make the patient unsuitable for this study or significantly interfere with the assessment of safety and toxicity.",{"count":223,"type":21},[401],"PHASE2","Phase II, Multicenter, Open-label, Randomized Study evaluating neoadjuvant chemotherapy (FOLFOX4) in patients with stage II and III colorectal cancer with standard chemoradiation Defined by Magnetic Resonance Imaging",[404],"Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX","2022-05-12",{"date":407,"type":38},"2022-05-18",{"date":409,"type":38},"2015-06-01",{"date":411,"type":21},"2027-06-01",{"name":44,"class":45},""]